Japanese Journal of Ophthalmology

, Volume 63, Issue 1, pp 40–45 | Cite as

Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil in Japanese patients with various subtypes of glaucoma

  • Takashi Komizo
  • Takashi Ono
  • Akiko Yagi
  • Kazunori Miyata
  • Makoto AiharaEmail author
Clinical Investigation



The present study aimed to investigate the effectiveness of adjunctive therapy involving the Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitor ripasudil in lowering intraocular pressure (IOP) in patients with different subtypes of glaucoma, on the basis of the time of IOP measurement

Study design

Retrospective study


In total, 58 patients who underwent adjunctive therapy with ripasudil at a single institution were included. They were classified into a primary open-angle glaucoma (POAG) group, an exfoliation glaucoma (XFG) group, and a secondary glaucoma associated with uveitis, or steroid glaucoma (SG), group. The average IOPs within 6 months before (pre-IOP) and after (post-IOP) the addition of ripasudil were compared among the 3 groups. The IOP values of the morning-visit and afternoon-visit groups were also compared to reflect the peak effectiveness of ripasudil.


The IOP reductions in the POAG (n = 38), XFG (n = 6), and SG (n = 14) groups were −1.1, +0.5, and +0.5 mmHg, respectively. Significant reductions in IOP were observed in the POAG group (P = .014). The IOP reductions in the POAG morning-visit and afternoon-visit groups were −1.9 and +0.5 mmHg, respectively. IOP was significantly reduced in the morning-visit POAG group after treatment with ripasudil (P = .002). The IOP values measured during morning visits were lower than those measured during afternoon visits (IOP reduction: −1.3 mmHg; P = .011).


The findings of the present study indicate that ripasudil is effective as an adjunctive therapy for lowering IOP in patients with POAG; these reductions are more significant when measured closer to the time of peak effectiveness.


Glaucoma Intraocular pressure Rho-kinase inhibitor Ripasudil 


Conflicts of interest

T. Komizo, Lecture fee (Kowa); T. Ono, Lecture fees (Bayer, Kowa, Santen, Senju); A. Yagi, None; K. Miyata, Grant (Novartis, Otsuka, Santen, Senju), Lecture fees (Kowa, Novartis, Otsuka, Pfizer, Santen, Senju); M. Aihara, Grant (Alcon, Pfizer), Consultant fees (Crewt Medical Systems, Glaukos, HOYA, Otsuka, Santen, Senju, WaKamoto), Lecture fees (Abbot, Alcon, Allergan, Crewt Medical Systems, HOYA, JFC Sales Plan, Kowa, Nitten, Otsuka, Pfizer, Santen, Senju, WaKamoto).


  1. 1.
    Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498–505.CrossRefGoogle Scholar
  2. 2.
    Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268–79.CrossRefGoogle Scholar
  3. 3.
    Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–13.CrossRefGoogle Scholar
  4. 4.
    Kook MS, Simonyi S, Sohn YH, Kim CY, Park KH. Bimatoprost 0.01% for previously treated patients with open-angle glaucoma or ocular hypertension in the Korean clinical setting. Jpn J Ophthalmol. 2015;59:325–34.CrossRefGoogle Scholar
  5. 5.
    Cho SY, Kim YY, Yoo C, Lee T. Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. Jpn J Ophthalmol. 2016;60:27–34.CrossRefGoogle Scholar
  6. 6.
    Shoji N, Kasahara M, Iijima A, Takahashi M, Tatsui S, Matsumura K, et al. Short-term evaluation of trabectome surgery performed on Japanese patients with open-angle glaucoma. Jpn J Ophthalmol. 2016;60:156–65.CrossRefGoogle Scholar
  7. 7.
    Tanaka D, Nakanishi H, Hangai M, Akagi T, Morooka S, Ikeda HO, et al. Influence of high myopia on outcomes of trabeculectomy with mitomycin C in patients with primary open-angle glaucoma. Jpn J Ophthalmol. 2016;60:446–53.CrossRefGoogle Scholar
  8. 8.
    Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, et al. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016;6:19640.CrossRefGoogle Scholar
  9. 9.
    Xu N, Chen SH, Qu GY, Li XD, Lin W, Xue XY, et al. Fasudil inhibits proliferation and collagen synthesis and induces apoptosis of human fibroblasts derived from urethral scar via the Rho/ROCK signaling pathway. Am J Transl Res. 2017;9:1317–25.Google Scholar
  10. 10.
    Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007;48:5549–57.CrossRefGoogle Scholar
  11. 11.
    Futakuchi A, Inoue T, Fujimoto T, Inoue-Mochita M, Kawai M, Tanihara H. The effects of ripasudil (K-115), a Rho kinase inhibitor, on activation of human conjunctival fibroblasts. Exp Eye Res. 2016;149:107–15.CrossRefGoogle Scholar
  12. 12.
    Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost. JAMA Ophthalmol. 2015;133:755–61.CrossRefGoogle Scholar
  13. 13.
    Sato S, Hirooka K, Nitta E, Ukegawa K, Tsujikawa A. Additive intraocular pressure lowering effects of the Rho kinase inhibitor, Ripasudil in glaucoma patients not able to obtain adequate control after other maximal tolerated medical therapy. Adv Ther. 2016;33:1628–34.CrossRefGoogle Scholar
  14. 14.
    Inoue K, Okayama R, Shiokawa M, Ishida K, Tomita G. Efficacy and safety of adding ripasudil to existing treatment regimens for reducing intraocular pressure. Int Ophthalmol. 2018;38:93–8.Google Scholar
  15. 15.
    Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. One-year efficacy of adjunctive use of Ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled with maximum medical therapy. Graefes Arch Clin Exp Ophthalmol. 2017;255:2009–15.CrossRefGoogle Scholar
  16. 16.
    Matsumura R, Inoue T, Matsumura A, Tanihara H. Efficacy of ripasudil as a second-line medication in addition to a prostaglandin analog in patients with exfoliation glaucoma: a pilot study. Clin Drug Investig. 2017;37:535–9.CrossRefGoogle Scholar
  17. 17.
    Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Suganami H, et al. Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study. Acta Ophthalmol. 2015;93:e254–60.CrossRefGoogle Scholar
  18. 18.
    Tanihara H, Inoue T, Yamamoto T, Kuwayama Y, Abe H, Fukushima A, et al. One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension. Acta Ophthalmol. 2016;94:e26–34.CrossRefGoogle Scholar
  19. 19.
    Inazaki H, Kobayashi S, Anzai Y, Satoh H, Sato S, Inoue M, et al. Efficacy of the additional use of ripasudil, a rho-kinase inhibitor, in patients with glaucoma inadequately controlled under maximum medical therapy. J Glaucoma. 2017;26:96–100.Google Scholar
  20. 20.
    Naumann GO, Schlötzer-Schrehardt U, Küchle M. Pseudoexfoliation syndrome for the comprehensive ophthalmologist: intraocular and systemic manifestations. Ophthalmology. 1998;105:951–68.CrossRefGoogle Scholar
  21. 21.
    Rohen JW, Linnér E, Witmer R. Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma. Exp Eye Res. 1973;17:19–31.CrossRefGoogle Scholar

Copyright information

© Japanese Ophthalmological Society 2018

Authors and Affiliations

  • Takashi Komizo
    • 1
  • Takashi Ono
    • 1
  • Akiko Yagi
    • 1
  • Kazunori Miyata
    • 1
  • Makoto Aihara
    • 2
    Email author
  1. 1.Miyata Eye HospitalMiyakonojoJapan
  2. 2.Department of Ophthalmology, Faculty of MedicineUniversity of TokyoBunkyoJapan

Personalised recommendations